Dual antithrombotic therapy in PCI: Potential harm in routine adoption

Key Points Randomized clinical trials support the use of dual antithrombotic therapy (DAT) in PCI patients but outcomes in clinical practice are unclear. In this observational study of patients at high risk for thromboembolism and bleeding, routine use of a P2Y12 inhibitor alone compared with DAPT w...

Full description

Saved in:
Bibliographic Details
Published in:Catheterization and cardiovascular interventions 2019-02, Vol.93 (3), p.E185-E186
Main Authors: Sardar, Partha, Dawn Abbott, J.
Format: Article
Language:English
Subjects:
Atrial Fibrillation
Bleeding
Clinical trials
Fibrinolytic Agents
Humans
Ischemia
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors
Randomization
Thromboembolism
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Key Points Randomized clinical trials support the use of dual antithrombotic therapy (DAT) in PCI patients but outcomes in clinical practice are unclear. In this observational study of patients at high risk for thromboembolism and bleeding, routine use of a P2Y12 inhibitor alone compared with DAPT with OAC was associated with a significantly higher risk of ischemic events without a lower risk of bleeding. Future randomized trials and observational analyses of large registries are needed to select the ideal patient population for DAT.
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.27999